BG34-200 / Case Western Reserve University - LARVOL DELTA

Carbohydrate ligand engagement with CD11b enhances differentiation of tumor-associated myeloid cells for immunotherapy of solid cancers. (PubMed, J Immunother Cancer) - "Our research has advanced the current understanding of the molecular basis of CD11b activation in solid cancers, revealing how it converts the differences in BG34 carbohydrate ligands into immune signaling responses. These findings could pave the way for the development of safe and novel BG34-200-based therapies that modulate myeloid-derived cell functions, thereby enhancing immunotherapy for solid cancers."

Journal • Gastrointestinal Cancer • Immune Modulation • Immunology • Melanoma • Oncology • Osteosarcoma • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Sarcoma • Solid Tumor • ICAM1 • ITGAM

Carbohydrate-CD11b engagement enhances differentiation of tumor-associated myeloid cells in immunotherapy of solid cancers (AACR 2023) - "Our findings improve understanding of molecular basis by which CD11b converts difference in carbohydrate ligands into subsequent immune signaling responses, may lead to development of safe and novel therapies modulating myeloid derived cell function for immunotherapy of solid cancers."

Gastrointestinal Cancer • Melanoma • Oncology • Osteosarcoma • Pancreatic Cancer • Sarcoma • Solid Tumor • ICAM1 • ITGAM

BG34-200 immunotherapy of advanced melanoma (AACR 2023) - "The scientific findings from this study will allow us to develop new technology to apply BG34-200-based immunotherapy to patients with advanced melanoma who have not responded to current standard of care therapies with and without immunotherapy."

Metastases • Melanoma • Oncology • Solid Tumor • ITGAM